What is Polaryx Therapeutics, Inc. 's net change in cash?

Polaryx Therapeutics, Inc. (PLYX) reported net change in cash of -206,300,000% in Q1 2026.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Akamai TechnologiesAKAM

-$304.37M-152%

BiogenBIIB

$392.2M+108%

UDRUDR

-$2.13M-1.3%

Vertiv Holdings CoVRT

$401.4M+64.6%

Henry ScheinHSIC

-$18M-460%

Keysight TechnologiesKEYS

$235M-77.8%

Operating income-$2.0M+61.2%

Net income-$2.5M+49.6%

EPS (diluted)-$0.05+54.5%

Cash & equivalents$3.1M+1,132%

Total equity$2.5M-41.5%

Total assets$3.5M—

Operating cash flow-$2.1M-191%

Market cap$115.64M—

Return on equity-1,209.8%—

Current ratio3.5×—

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Polaryx Therapeutics, Inc. 's net change in cash?: Polaryx Therapeutics, Inc. (PLYX) reported net change in cash of -206,300,000% in Q1 2026.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.